Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations

NCT02847598 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02847598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02847598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2016
Completion date
November 18, 2019
Enrollment
264 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

active cutaneous lupus erythematosus, systemic lupus erythematosus